Search Results - "Selvadurai, Hiranjan"

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study by Rosenfeld, Margaret, Wainwright, Claire E, Higgins, Mark, Wang, Linda T, McKee, Charlotte, Campbell, Daniel, Tian, Simon, Schneider, Jennifer, Cunningham, Steve, Davies, Jane C, Rosenfeld, Margaret, Wainwright, Claire E., Higgins, Mark, Wang, Linda T., McKee, Charlotte, Campbell, Daniel, Tian, Simon, Schneider, Jennifer, Cunningham, Steve, Davies, Jane C., Harris, William, Mogayzel, Peter, McCoy, Karen, Milla, Carlos, Rubenstein, Ronald, Walker, Seth, Black, Philip, Montgomery, Gregory, McColley, Susanna, Hiatt, Peter, Sawicki, Gregory, Rock, Michael, Aurora, Paul, Ratjen, Felix, Maitra, Anirban, Ives, Andrew, Gaillard, Erol, McNalley, Paul, Selvadurai, Hiranjan, Robinson, Philip

“…Ivacaftor is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. We assessed its use in…”
Get full text

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial by Ratjen, Felix, Prof, Hug, Christopher, MD, Marigowda, Gautham, MD, Tian, Simon, MD, Huang, Xiaohong, PhD, Stanojevic, Sanja, PhD, Milla, Carlos E, MD, Robinson, Paul D, MBChB, Waltz, David, MD, Davies, Jane C, Prof

“…Summary Background Lumacaftor and ivacaftor combination treatment showed efficacy in patients aged 12 years or older with cystic fibrosis homozygous for…”
Get full text

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study by Flume, Patrick A, Downey, Damian G, Brown, Cynthia, Fischer, Rainald, De Boeck, Kris, Chang, Philip, Rubin, Jaime L, Yang, Yoojung, Wang, Xin, Ahluwalia, Neil, Owen, Caroline A, Ahrens, Richard C., Aitken, Moira, McBennett, Kimberly Ann, Pilewski, Joseph M., Billings, Joanne, Linnemann, Rachel, Powers, Michael R., Frederick, Carla Anne, Black, Philip, Berdella, Maria, Brown, Cynthia D., Anstead, Michael, Sicilian, Leonard, Moffett, Kathryn, Nasr, Samya, Taylor-Cousar, Jennifer, Barto, Tara Lynn, Antos, Nicholas, Quick, Bryon, Thompson, Henry R., Sawicki, Gregory, Smith, Thomas C., Schultz, Karen D., Omlor, Gregory J., Mehdi, Nighat, Ortiz, Maria Gabriela Tupayachi, Gardner, Tonia E., Jain, Raksha, Berlinski, Ariel, Calimano, Francisco J., Lascano, Jorge E., McWilliams, Bennie, Morrissey, Brian, Chittivelu, Subramanyam, Klingsberg, Ross, Biller, Julie A., Bui, Stephanie, Sommerburg, Olaf, Bignamini, Elisabetta, Collura, Mirella, Bentur, Lea, Efrati, Ori, Gallego, Esther Quintana, Barry, Peter, Asensi, Jose Ramon Villa, Armstrong, David Stuart, de la Cruz, Oscar Asensio, Gilchrist, Francis, Lands, Larry C., Lavoie, Annick, Linnane, Barry, Elidemir, Okan, Ringshausen, Felix, Kappler, Matthias, Hebestreit, Helge, Mainz, Jochen, Staab, Doris, Gleiber, Wolfgang, Pressler, Tacjana, Ketchell, Robert Ian, Doe, Simon, Nash, Edward Fairbairn, Peckham, Daniel Gavin, Kansra, Sonal, Delaisi, Bertrand, Le Bihan, Jean, Fajac, Isabelle, Sermet-Gaudelus, Isabelle, De Boeck, Christiane, Reix, Philippe, van Braeckel, Eva, Prevotat, Anne, van der Meer, Renske, Weersink, E.J.M., Gartner, Silvia, Jover, Amparo Sole, Fernandez, Antonio Alvarez, Cox, Desmond William, McKone, Edward F., Bowler, Simon David, Wainwright, Claire Elizabeth, Wilson, John William, Volpi, Sonia, Colombo, Carla, Fabrizzi, Benedetta, Lucidi, Vincenzina, Cucchiara, Salvatore, Eber, Ernst, Krantz, Christina

“…Tezacaftor–ivacaftor is an approved cystic fibrosis transmembrane conductance regulator (CFTR) modulator shown to be efficacious and generally safe and well…”
Get full text